Janus kinase 1 (tyrosine-protein kinase JAK1, JAK-1, JAK1, JAK1A, JAK1B)
Jump to navigation
Jump to search
Function
- tyrosine kinase of the non-receptor type
- role in IFN-alpha/beta/gamma signal pathway
- kinase partner for IL-2 receptor
- interacts with IL31RA & SHB
Structure
- 2 phosphotransferase domains
- domain 2 probably contains the catalytic domain
- domain 1 probably has a different role
- belongs to the Tyr protein kinase family, JAK subfamily
- contains 1 FERM domain
- contains 1 protein kinase domain
- contains 1 SH2 domain
Compartment
- intracytoplasmic membrane, peripheral membrane (putative)
- wholly intracellular, possibly membrane associated
Pharmacology
- upadacitinib, an inhibitor of JAK-1 is an investigational agent for treatment of refractory rheumatoid arthritis[2]
- filgotinib an inhibitor of JAK-1 is another investigational agent for treatment of refractory rheumatoid arthritis[3]
More general terms
References
- ↑ Ihle JN et al Signaling by the cytokine receptor superfamily: JAKs and STATs TIBS 19:222 1994 PMID: https://www.ncbi.nlm.nih.gov/pubmed/8048164
- ↑ 2.0 2.1 UniProt http://www.uniprot.org/uniprot/P23458.html
- ↑ 3.0 3.1 McNamara D JAK-1 Inhibitor Effective for RA, but Safety Signal Troubles. Medscape - Nov 13, 2017. https://www.medscape.com/viewarticle/888522
- ↑ Genovese MC, Kalunian K, Gottenberg JE et al Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease- Modifying Antirheumatic Drug TherapyThe FINCH 2 Randomized Clinical Trial. JAMA. 2019;322(4):315-325 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31334793 https://jamanetwork.com/journals/jama/fullarticle/2738551
Singh JA Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis. JAMA. 2019;322(4):309-311 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31334773 https://jamanetwork.com/journals/jama/fullarticle/2738528